DA3532 VEGFR-1 / Flt-1 antigen
see all 45 VEGFR-1 / Flt-1 products
5 µg / US$ 225
NOVUS BIOLOGICALS
PO Box 802 Littleton, CO 80160, USA
E-Mail: novus@novus-biologicals.com
Homepage: http://www.novus-biologicals.com
PO Box 802 Littleton, CO 80160, USA
E-Mail: novus@novus-biologicals.com
Homepage: http://www.novus-biologicals.com
Quick Overview
Human VEGFR-1 / Flt-1
Synonyms
FLT1, FLT, FRT, VEGFR1, , Vascular Endothelial Growth Factor Receptor 1, Vascular permeability factor receptor, Tyrosine-protein kinase receptor FLT, Tyrosine-protein kinase FRT, Fms-like tyrosine kinase 1
Product review
Please read our product review about VEGFR-1 / Flt-1: Antibodies to Vascular Endothelial Growth Factor Receptor (VEGFR) Family: VEGFR-1 antibody, VEGFR-2 antibody and VEGFR-3 antibody.
Product Description
Human VEGFR-1 / Flt-1
Properties
| Presentation | Purified |
| Species | Human |
| Purity | >85% |
| Source | Insect cells |
| Molecular Weight | 96 kD |
| Catalog Number | DA3532 |
| Swiss Prot. No. | P17948 |
| Quantity | 5 µg |
| Price | US$ 225 |
| Delivery | Worldwide |
| Manufacturer | Acris Antibodies GmbH |
| Datasheet | view  DA3532.pdf |
Datasheet Extract
| Background | Endothelial cells express three different vascular endothelial growth factor (VEGF) receptors, belonging to the family of receptor tyrosine kinases (RTKs). They are named VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk-1), and VEGFR-3 (Flt-4). Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes, dendritic cells and on trophoblast cells. The flt-1 gene was first described in 1990. The receptor contains seven immunoglobulin -like extracellular domains, a single transmembrane region and an intracellular split tyrosine kinase domain. Compared to VEGFR-2 the Flt-1 receptor has a higher affinity for VEGF but a weaker signaling activity. VEGFR-1 thus leads not to proliferation of endothelial cells, but mediates signals for differentiation. Interestingly, a naturally occuring soluble variant of VEGFR-1 (sVEGFR-1) was found in HUVEC supernatants in 1996, which is generated by alternative splicing of the flt-1 mRNA. The biological functions of sVEGFR-1 still are not clear, but it seems to be an endogenous regulator of angiogenesis, binding VEGF with the same affinity as the full-length receptor.
|
| Immunogen | Swiss Num.: P17948 |
| Source | Insect cells |
| Format | State: Lyophilised, without buffer and stabilizer Purity: > 90% by SDS-PAGE and visualised by silver stain Endotoxinlevel: < 0.1 ng per µg of sVEGFR-1 Reconstitution: Soluble in water and most aqueous buffers. The lyophilized sVEGFR-1 should be reconstitited in PBS to a concentration not lower than 100µg/ml. |
| Description | Recombinat human soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1) is the naturally occurring form and was cloned from total RNA of human umbilical vein endothelial cells. The recombinant mature sVEGFR-1 is a glycosylated monomeric protein with a mass of approximately 96 kDa. The soluble receptor protein contsists of the first 6 extracellular domains (Met1-His688) containing the unique 31 amino acids residues at the
C-terminus. Biological Activity: The activity of sVEGFR-1 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surface receptors. The ED50 for this effect is typically 10 ng/ml. |
| Storage | Lyophilised samples are stable for one year from despatch at -20°C to -70°C.
Reconstituted sVEGFR-1 should be stored in working aliquots at -20°C. Avoid repeated freeze-thaw cycles! |
| References | 1. Röckl et al., Exp Cell Res 241:161, 1998
2. Barleon et al., J Biol Chem 272:10382, 1997 |